Indian pharmaceutical companies have the second-highest US FDA approved plants (after the United States) for both active pharmaceutical ingredients (APIs) and formulations. As Indian pharma accounts form a significant share of the US generic market, there is increased scrutiny of the manufacturing facilities by US FDA over the last two years. Moreover, several facilities in India are awaiting US FDA re-inspection and there is a significant number of pending abbreviated new drug applications (ANDAs) and drug master files with the US FDA.

This DigiConnect is going to be a 90-minute discussion which brings together senior experts from pharmaceutical, lifesciences and chemical companies from across India, who have numerous assets like lab equipment, storage tanks, fire safety, trucks/forklifts among other to discuss the current approach towards asset management and compliance in the industry and the importance of making the shift from reactive to prescriptive approach.